Trial Profile
Single-Center, Open-Labeled Dose Escalation Followed by Randomized, Double-Blind, Placebo-Controlled Cohort Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Regrelor (Primary)
- Indications Thrombosis
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 05 Nov 2010 New trial record.